



THE REACTION TIMES

All the news that's fit to react to.

Published twice a year by the ACS Division of Medicinal Chemistry



Volume 16, Number 2

Summer Newsletter

July, 2017

Abstracts for the Washington ACS Meeting Available for Download

Abstracts for the upcoming Washington ACS meeting are available on the Division web site. Follow the link below for the MEDI abstracts:

www.acsmedchem.org/?nd=nationalmeetings

Quick Reference Guide to Services

Division Web Site: www.acsmedchem.org

Division Hall of Fame:
www.acsmedchem.org/?nd=hof

Division Awards and Prizes
www.acsmedchem.org/?nd=awards

Link to Division Newsletter Archive:
www.acsmedchem.org/?nd=newsletters

Link to Archived MEDI Meeting Abstracts:
www.acsmedchem.org/?nd=nationalmeetings

ACS Web Page
portal.acs.org

Journal of Medicinal Chemistry
pubs.acs.org/journal/jmcmr

2017 Executive Committee Members

2017 Chair: Wendy B. Young
2017-2018 Program Chair: Andrew W. Stamford
2017 Vice-Chair: Paul Ornstein
Industrial Councilor 2016-18: Amy Ripka
Industrial Councilor 2015-17: William J. Greenlee
Academic Councilor 2017-19: Jane Aldrich
Academic Councilor 2015-17: Craig W. Lindsley
Secretary/PR Chair 2017-19: D. Eric Walters
Membership & Intl. Chair: Patrick M. Woster
Treasurer 2015-17: David P. Rotella
2017 Past Chair: Thomas Bannister

Contact information for all Division Officers appears at the end of this Newsletter.

Scientific Program for the 254th ACS Meeting, Washington, DC (Aug 20-24, 2017)

(ACS Abstract system now closed for this meeting)

SUN AM	Chronic Neuropathic Pain
SUN AM	General Oral Session I
SUN PM	Biophysical Methods in Drug Discovery
SUN PM	General Oral Session II
SUN EVE	Poster Session I and Social Hour
MON AM	Insights From Hardcore Practitioners
MON AM	Addiction: The Unmet Need
MON PM	Emerging Platforms for Drug Discovery
MON PM	CYP450 Enzymes As Targets
TUES AM	Scarborough & Portuguese Awards
TUES AM	Recent Advances in HIV Treatment
TUES PM	Allosteric Modulators of GPCRs & Ion Channels
TUES PM	General Oral Session III
WED AM	First Time Disclosures
WED AM	Unusual Protein-Ligand Interactions
WED PM	First Time Disclosures
WED PM	General Oral Session IV
WED EVE	Poster Session II & Social Hour (w/ORGN)

Scientific Program for the 255th ACS Meeting, New Orleans, LA (March 18-22, 2018)

(ACS Abstract system open soon, maps.acs.org)

SUN AM	Leveraging Atropisomers
SUN AM	General Oral Session I
SUN PM	Dipole and Charge in Drug Design (Toolbox)
SUN PM	General Oral Session II
SUN EVE	Poster Session I and Social Hour
MON AM	Small Molecule "Breakthrough Therapies"
MON AM	Ubiquitinase Inhibitors
MON AM	Gasotransmitters
MON PM	Selective PI3K Inhibitors
MON PM	Clinical Candidates from Phenotypic Screens
MON PM	MEDI Young Investigators Symposium
TUES AM	Remarkable Scientists of Medicinal Chemistry
TUES AM	Treating Retinal Disease with Small Molecules
TUES AM	General Oral Session III
TUES PM	Award Session
TUES PM	Boron in Medicinal Chemistry
WED AM	First Time Disclosures
WED AM	Small Molecules Targeting RNA
WED PM	First Time Disclosures
WED PM	General Oral Session IV
WED EVE	Poster Session II & Social Hour (w/ORGN)

Rolf Hartmann is Awarded Portuguese Lectureship



The American Chemical Society's Division of Medicinal Chemistry and the *Journal of Medicinal Chemistry* are pleased to announce that **Rolf Hartmann** has been selected as the 2017 recipient of the eighth Philip S. Portuguese Medicinal Chemistry Lectureship. This award is named in honor of Phil Portuguese, the long-standing Editor-in-Chief of the *Journal of Medicinal Chemistry*. The Lectureship is administered jointly by the Editor-in-Chief of the *Journal* and the ACS Division of Medicinal Chemistry. The objective of the lectureship is to honor the contributions of an individual who has had a major impact on medicinal chemistry research. The award is funded principally by the *Journal of Medicinal Chemistry* (ACS Publications Division) and the awardee is selected by a committee appointed jointly by the *Journal* and the Division of Medicinal Chemistry. Dr. Hartmann will receive the award and give the award address at the 254th National American Chemical Society Meeting in Washington, DC, on Tuesday, August 22.

Dr. Hartmann is Professor of Pharmaceutical and Medicinal Chemistry at Saarland University and Department Head at the Helmholtz Institute of Pharmaceutical Research Saarland, Germany. He is an internationally well-known expert in the field of steroidogenic drug targets and has discovered potent and selective inhibitors of steroidogenic enzymes like aromatase, CYP17, aldosterone synthase, CYP11B1 and 17betaHSD1 and 2. More recently he started research on innovative pathoblocker concepts to find novel anti-infectives less prone to resistance development. In addition to being an academic teacher, Professor Hartmann is a successful entrepreneur and inventor. He founded three companies and has numerous patents. He published more than 330 papers in peer-reviewed international journals, approximately 70 in the *Journal of Medicinal Chemistry*. Dr. Hartmann graduated from the Technical University of Munich, received his PhD and Habilitation from the University of Regensburg and subsequently was appointed Professor at the Free University of Berlin. At Saarland University he served as vice-president and deputy president. Prof Hartmann has received a number of awards, for example the Carl-Mannich Medal of the German Pharmaceutical Society.

Plan to Submit Abstracts for Spring Meeting in New Orleans

You are invited to submit an **abstract for a research presentation** at the Spring ACS National Meeting, which will be held March 18-22, in New Orleans, LA. Abstract submission will open soon at maps.acs.org.

The Division of Medicinal Chemistry makes available a limited number of grants of \$1000 annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS regular or student members, and not have previously received a travel award. To apply for **MEDI student travel grants**, go to www.acsmedchem.org/?nd=travelgrants. Deadline for application is the same as for abstract submission. Awardees will be notified in sufficient time so that they can pre-register for the meeting. **All travel grant recipients are required to acknowledge the Division in a slide or on their poster as a condition of accepting the award.** Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Address info and a complete application appears on the website.

Chemical Computing Group is offering student travel grants for student presentations (in oral or poster format) that include a computational chemistry component. Winners receive \$1,150 to offset their travel expenses, as well as a copy of CCG's MOE (Molecular Operating Environment) software with a one-year license. Go to www.acsmedchem.org/?nd=ccgawards for details. Deadline for application is the same as for abstract submission.



flare ...trailblazer!

new insights into
structure-based design

docking




water analysis

protein electrostatics

flare

ligand energetics




New application for understanding your protein-ligand system

Request **FREE** evaluation: cresset-group.com/flare

2017 Hall of Fame Inductees Announced

The Division is pleased to announce that four medicinal chemists, **Stanley T. Crooke**, **Gunda Georg**, **Michael Rowley**, and **Michael J. Sofia**, will be inducted into the ACS Division of Medicinal Chemistry Hall of Fame at the Washington ACS meeting. The induction ceremony will be held on Tuesday, August 22, 2016, from 5:30 - 7:30 p.m., in rooms 150 A & B at the Washington Convention Center.



Dr. Stanley Crooke is founder, chairman, and chief executive officer of Ionis Pharmaceuticals. During his tenure at Ionis, he has led the scientific development of a new platform for drug discovery, antisense technology and engineered the creation of one of the largest and more advanced development pipelines in the biotechnology industry. Early in Dr. Crooke's career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D at SmithKline Beckman. Dr. Crooke has received a number of awards, most recently, the American Chemical Society's E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society and the Scrip Lifetime Achievement Award. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. He has published more than 475 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 21 drugs that have been commercialized.

Dr. Gunda Georg received her B.S. in pharmacy and her Ph.D. from the University of Marburg, Germany. She joined the faculty of the University of Kansas, where she founded the Center of



Biomedical Research Excellence for Cancer Experimental Therapeutics and rose to the title of University Distinguished Professor. Dr. Georg was recruited to the University of Minnesota in 2007 as Head of the Department of Medicinal Chemistry. She founded the Institute for Therapeutics Discovery and Development, which is devoted to moving discovery stage projects through drug development stages to Phase I clinical trials. Her research has covered a wide range of targets, including cancer (analogs of taxol, epithilone, cryptophycin, and minnelide, a triptolide analog), Alzheimer's disease (tubulin binders), epilepsy (prodrugs of diazepam), and non-hormonal contraceptives (gamendazole). Lusedra™ is a prodrug of the general anesthetic propofol. Dr. Georg holds the Robert Vince Endowed Chair in Medicinal Chemistry and a McKnight Presidential Chair. She serves the profession as Co-Editor-in-Chief of the *Journal of Medicinal Chemistry* and has been an active member of the

Division of Medicinal Chemistry.



Dr. Mike Rowley studied in Cambridge, receiving his MA and PhD. He spent two years as a postdoc with Yoshito Kishi at Harvard University, completing the total synthesis of Ophiobolin C. In 1988 he joined Merck Sharp and Dohme in the UK as a medicinal chemist, in various neuroscience projects. In 2000, Mike moved to become responsible for Medicinal Chemistry and DMPK at the Istituto di Ricerche di Biologia Molecolare (IRBM - MSD's site in Rome), working in the areas of antivirals and cancer. It was during this time that the group in Rome, with the MRL site West Point, discovered raltegravir (Isentress™), the first in class inhibitor of HIV integrase. This was followed by IRBM's discoveries of grazoprevir, an HCV protease inhibitor approved in a combination therapy as Zepatier™ for hepatitis C virus infection and of niraparib (Zejula™), a PARP inhibitor used for ovarian cancer. Following the closure of the IRBM, he joined AstraZeneca in Mölndal, Sweden. Mike led work in lead generation and

optimization, computational chemistry and scale up covering cardiovascular, gastrointestinal, diabetes and obesity projects. He returned to MSD in 2012 as Associate Scientific Vice President, based in Luzern, Switzerland. Mike returned to the UK in 2016, and joined Pharmaron as Senior Vice President, Drug Discovery Services Europe in 2017. He has published over 100 papers and 40 patent applications. Mike is a Fellow of the Royal Society of Chemistry and received the ACS Heroes of Chemistry award in 2013.



Dr. Michael J. Sofia received his Ph.D. in organic chemistry at the University of Illinois. He joined Prof. Gilbert Stork at Columbia University as an NIH Postdoctoral Fellow. Dr. Sofia began his industrial career at Squibb where he developed inhibitors of squalene synthetase and HMG-CoA. His work led to the identification of the first potent substrate-based inhibitor of squalene synthetase. In 1989 Dr. Sofia joined Eli Lilly & Company, where he spearheaded work in the area of leukotriene B4 receptor antagonists for the treatment of inflammation associated with asthma and delivered the clinical candidate LY293111 which progressed to phase II clinical trials. In 1993 Dr. Sofia joined Transcell Technologies as the founding Director of Chemistry, where he pioneered the development of carbohydrate-based technologies for combinatorial chemistry and anti-infective drug discovery. In 1999, Dr. Sofia joined Bristol-Myers Squibb where he built a lead discovery chemistry

organization. Dr. Sofia left BMS in 2005 to join Pharmasset, Inc. His work led to multiple clinical candidates including agents targeting the hepatitis C virus (HCV). His work on HCV resulted in the development of the HCV NS5B polymerase inhibitor, sofosbuvir that utilized a novel liver-targeted prodrug strategy. In 2013 sofosbuvir became the first interferon-free HCV cure therapy approved by both the US FDA and the European EMEA and was marketed as Sovaldi®. Dr. Sofia has authored over 100 publications, 12 book chapters and numerous abstracts and is an inventor on more than 53 US patents and numerous patent applications. He is the recipient of numerous awards, including the 2015 Heroes of Chemistry Award of the American Chemical Society, the 2016 IUPAC-Richter Prize in Medicinal Chemistry, and the 2016 Lasker-DeBakey Award in Clinical Medical Research.



19th TETRAHEDRON SYMPOSIUM

26–29 June 2018

RIVA DEL GARDA, LAKE GARDA, ITALY

Celebrating the 25th Anniversary of
Bioorganic and Medicinal Chemistry



Submit abstracts by 12 January 2018



www.elsevier.com/tetrahedron-symposium



ACSMEDI-
EFMC
Medicinal
Chemistry
Frontiers

2017



**ACSMEDI-EFMC Medicinal
Chemistry Frontiers 2017**

June 25–28, 2017
Philadelphia, PA

The ACS MEDI-EFMC Medicinal Chemistry Frontiers 2017 meeting was held in Philadelphia PA, on June 25–28 of this year. This symposium was the sixth in the series initiated in Siena, Italy in 2007 and continued in Barcelona, Spain in 2009, Stockholm, Sweden in 2011, San Francisco, CA in 2013 and Antwerp, Belgium in 2015. The meeting is co-organized by the European Federation of Medicinal Chemistry and the American Chemical Society Division of Medicinal Chemistry.

The organizers wish to acknowledge their generous sponsors:

**AbbVie
Amgen
Bristol-Myers Squibb
Celgene
EMD Serono
Genentech
Gilead
Sanofi
Vertex**



Call for Nominations: 2018 Division of Medicinal Chemistry Award

Nominations are now being accepted for the 2018 Division of Medicinal Chemistry Award. The Division of Medicinal Chemistry award consists of three thousand dollars, a plaque and travel expenses incidental to receiving the Award. The award will be presented as a part of a special session at the 2018 National Medicinal Chemistry Symposium to be held in Nashville, TN, April 29 – May 2, 2018.

The Award shall be open to any scientist here or abroad, whose research has, directly or indirectly, had a significant effect on Medicinal Chemistry. Although other types of accomplishment (such as a new research tool or a biological discovery) shall not be excluded, emphasis shall be placed on (a) medicinal chemistry, (b) recent contributions, and (c) scientists whose accomplishments have not already been adequately recognized in the form of other honors. Research teams shall not be excluded as sharers of the Award.

Nominations must include a detailed letter describing the candidate's research accomplishments and contributions to medicinal chemistry, at least one seconding letter and a current curriculum vitae of the nominee(s). Materials must be submitted online by **September 1, 2017** at the website, where you can find further information and previous winners (www.acsmedchem.org/?nd=divisionaward) and the online nomination form (www.acsmedchem.org/?nd=vms_load_form&form_id=8).

36th National Medicinal Chemistry Symposium



The | NATIONAL MEDICINAL
36th | CHEMISTRY SYMPOSIUM

Nashville, TN | April 29th - May 2nd, 2018

The **36th National Medicinal Chemistry Symposium** will be held April 29-May 2, 2018, at the Sheraton Nashville Downtown Hotel. This will be the 36th in the series that was initiated in 1948. Meeting Co-chairs are Dr. Craig W. Lindsley, Vanderbilt University, and Dr. Maria J. Blanco, Sage Therapeutics. More information is available at www.nmcs.info.

Three Students Selected to Receive ACSMEDI Predoctoral Fellowships

The Division of Medicinal Chemistry is pleased to announce that three graduate students have been selected to receive 2017-2018 Predoctoral Fellowships. The awards, consisting of a \$26,000 stipend, are granted to predoctoral students in their third or fourth year of graduate study. Winners must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. Two of these awards are supported by the Medicinal Chemistry Division of ACS. One of the fellowships (that of Kelsey Lamb) is supported through the generosity of Division members Thomas Perun. The awardees for the 2017-2018 academic year are:



Deanna Montgomery, University of Michigan, Advisor: Henry Mosberg. Deanna received a B.S. in Chemistry from Houghton College in western New York. As an undergraduate, she participated in an NSF REU program at the University of California - Davis, where she worked in the lab of Mark Kurth on the synthesis of novel constrained bithiazoles as correctors of protein misfolding for potential treatment of cystic fibrosis. She is currently pursuing her Ph.D. in Medicinal Chemistry in the lab of Henry Mosberg at the University of Michigan. Her research focuses on the design, synthesis, and evaluation of novel multifunctional opioid peptidomimetics for potential use in the treatment of cocaine addiction and as analgesics with lowered abuse potential.



Kelsey Lamb, University of North Carolina, Advisor: Stephen Frye. Kelsey is originally from Fishers, IN. In 2014, she received her B.S. in Chemistry with Summa Cum Laude honors from Bellarmine University in Louisville, KY. She also competed in NCAA Division 2 basketball for all four years at Bellarmine. She was then accepted into the Division of Chemical Biology and Medicinal Chemistry through the Pharmaceutical Sciences PhD program at UNC Eshelman School of Pharmacy, and joined Stephen Frye's group in the spring of 2015. The Frye group is focused on the development of chemical probes for methyl lysine reader proteins, which are important regulators of gene expression. Her research is focused on the development of compounds for two distinct targets using both small molecule and peptidomimetic approaches, and the *in vitro* and *in vivo* testing of these compounds.

Hang Chu, Scripps Research Institute, Advisor: Phil S. Baran.

ACS Webinar Series: Drug Design and Delivery Symposium

The 2017 webinar series is organized by Nicholas Meanwell (Bristol-Myers Squibb), John Morrison (Bristol-Myers Squibb, and Annette Bak (AstraZeneca). The schedule includes:

August 17	Spinal Muscular Atrophy
September 28	Lupus
October 26	Psoriasis
November 30	Irritable Bowel Syndrome

For more information:

<https://www.acs.org/content/acs/en/acs-webinars/collections/2017-drug-design.html>

Sponsorship for Division of Medicinal Chemistry Symposia

Division of Medicinal Chemistry symposia at National Meetings are presented in part through the financial support of sponsor companies. Sponsorship opportunities are available for all upcoming Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are acknowledged with a prominent sign outside the meeting room, and by session chairs during the symposium. In addition, a table is provided where company representatives can interact with meeting attendees, and provide promotional materials. For more information on symposium sponsorship, contact the 2017 Program Chair, Andrew Stamford (andrew.stamford@merck.com), or the 2017 Division Chair, Wendy Young (young.wendy@gene.com).

The Division would like to thank the generous sponsors of our Washington symposia!

AbbVie
ACS Publications (*Journal of Medicinal Chemistry* and *ACS Med Chem Letters*)
Amgen
Astra Zeneca
Bristol-Myers Squibb
Celgene
Genentech
Gilead
Janssen
Paraza Pharma
Pfizer
Sanofi
Vertex
WuXi AppTec

Invitation to Authors: *Journal of Medicinal Chemistry Perspective Series*

The Perspective series of the *Journal of Medicinal Chemistry* is designed to provide an enlightened appraisal of a field of research in which experts review the state-of-the-art for a given area or therapeutic target. Authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility within the pharmaceutical industry and academia. We would like to identify a wide range of potential topics and authors to ensure that a Perspective article is published in every issue of the Journal. We would like the series to be useful to a broad range of scientists interested in the design, discovery and development of novel medicines. We invite you to submit an idea for a Perspective, along with a brief outline of what you will cover in the manuscript. We also welcome your input regarding potential topics of interest and authors for Perspective manuscripts. Please direct correspondence or calls regarding the series to:

William J. Greenlee
MedChem Discovery Consulting
115 Herrick Avenue
Teaneck, NJ 07666-4106
Phone (908)-463-5332
william@william-greenlee.com

Advertise in the ACSMEDI Newsletter

The ACSMEDI Newsletter is distributed twice a year to 9,000 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy:

Full page:	\$900.00
One-half page:	\$500.00
One-quarter page:	\$350.00

To place an ad or obtain more information, contact the editor at eric.walters@rosalindfranklin.edu


Division Archives Available On-line

Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These documents can be downloaded in pdf format through the Division WWW page:

<http://www.acsmedchem.org>

Medicinal Chemistry Reviews

Medicinal Chemistry Reviews is an outstanding 600 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling (US, \$30; International, \$50). Members should go to www.acsmedchem.org, use the 'Member Login', and then click on the 'Resources' tab. Volume 50 (2015) and Volume 51 (2016) are currently online. The 2017 volume will be available later this year.



ACS Division of Medicinal Chemistry Complete Officers/LRPC List 2017

1. Regular Executive Committee Members

Chair 2017



Wendy B. Young, Ph.D.
Director, Medicinal Chemistry
Genentech Inc.
1 DNA Way
MS#18
South San Francisco, CA 94080
Phone: 650-467-7945
young.wendy@gene.com

Secretary & Public Relations 2017-2019



D. Eric Walters, Ph.D.
Department of Pharmaceutical Sciences
Rosalind Franklin University
3333 Green Bay Road
North Chicago, IL 60064
847-578-8613
eric.walters@rosalindfranklin.edu

Vice Chair 2017



Paul Ornstein, Ph.D.
Associate Professor of Medicinal Chemistry
Roosevelt University
1400 N. Roosevelt Blvd
Schaumburg, IL 60605
847-330-4504
plornstein@roosevelt.edu

Membership & International Relationships



Patrick M. Woster, Ph.D.
Dept of Drug Discovery & Biomed.
Medical Univ. of South Carolina
70 President St., Room 405
Charleston, SC 29425
843-876-2453
woster@musc.edu

Program Chair 2017-2018



Tri-Institutional Therapeutics Discovery Institute
Belfer Research Building
413 East 69th St.
New York, NY 10021
646-962-6227
astamford@tritdi.org

Treasurer 2015-2017



David P. Rotella, Ph.D.
Department of Chemistry & Biochemistry
355 Richardson Hall
Montclair State University
Montclair NJ 07043
(973) 655-7204
rotellad@mail.montclair.edu

Academic Councilor 2017-2019



Jane Aldrich, Ph.D.
Department of Medicinal Chemistry
College of Pharmacy
University of Florida
P.O. Box 100485
Gainesville, FL 32610-0485
352-273-7714
jaldrich@cop.ufl.edu

Academic Councilor 2015-2017



Craig W. Lindsley, Ph.D. (2012-2014)
Pharmacology – Center for Neuroscience Drug
Discovery
12415D MRB IV (Langford)
Vanderbilt University Medical Center
Nashville, TN 37232-0697
(615)-322-8700
craig.lindsley@vanderbilt.edu

Industrial Councilor 2016-2018



Amy Ripka, Ph.D.
sar.consulting.llc@gmail.com

Industrial Councilor 2015-2017










William J. Greenlee, Ph.D.
MedChem Discovery Consulting, LLC
115 Herrick Avenue
Teaneck, NJ 07666-4106
(908) 463-5332
william@william-greenlee.com

Past Chair 2017



Thomas Bannister Ph.D.
Scripps Research Institute-Florida
130 Scripps Way
Jupiter, FL 33458
(561) 228-2206
tbannist@scripps.edu

2. Alternate Councilors & Other Ad Hoc EC Members

<p>Academic Alternate Councilor 2017-2019 Michael A. Walters, Ph.D. University of Minnesota 717 Delaware ST SE, Room 609 Minneapolis, MN 55414 612-626-6864 mwalters@umn.edu</p> 	<p>Academic Alternate Councilor 2015-2017 Carrie Haskell-Luevano University of Minnesota College of Pharmacy 308 Harvard Street SE Minneapolis, MN 55455 (612) 626-9262 chaskell@umn.edu</p> 
<p>Industrial Alternate Councilor 2016-2018 Maria-Jesus Blanco, Ph.D. Sage Therapeutics 215 First St, Suite 220 Cambridge, MA 02142 617-949-4132 maria-jesus.blanco@sagerx.com</p> 	<p>Industrial Alternate Councilor 2015-2017 Amjad Ali, Ph.D. Merck Research Laboratories 126 E. Lincoln Ave. Rahway, NJ 07065 (732) 594 8549 amjad_ali@merck.com</p> 
<p>Journal of Medicinal Chemistry Liaison 2017 Gunda Georg, Ph.D. Department of Medicinal Chemistry Editor, <i>Journal of Medicinal Chemistry</i> 717 Delaware Street SE College of Pharmacy University of Minnesota Minneapolis, MN 55414 (612)-626-6320 georg@umn.edu</p> 	<p>Editor-in-Chief, Annual Reports in Medicinal Chemistry (2017-2021) Joanne Bronson, Ph.D. Bristol-Myers Squibb 5 Research Parkway Wallingford, CT 06422 203-677-6431 joanne.bronson@bms.com</p> 
<p>Foreign Societies Liaison 2016 Thomas J. Perun, Ph.D. Affiliated Scientific 47731 Old Houston Hwy Hempstead, TX 77445 tjperun@aol.com</p> 	

Long Range Planning Committee 2017

LRPC Chair 2017



Paul Ornstein, Ph.D.

College of Pharmacy, Roosevelt University
1400 N. Roosevelt Blvd., Schaumburg, IL 60173
Phone: 847-330-4504
plornstein@roosevelt.edu



Gregory D. Cuny, Ph.D. (2016-2018)

University of Houston
Science and Research Building 2
3455 Cullen Blvd., Rm 549A
Houston, TX 77204-5037
713-743-1274
gdcuny@central.uh.edu



Jim Barrow, Ph.D. (2015-2017)

Room 336, John G. Rangos, Sr., Building,
855 N. Wolfe Street, Baltimore, MD 21205
410-955-0894
jbarrow@jhmi.edu



Lori Gavrin, Ph.D. (2016-2018)

GlaxoSmithKline
Office UP 1E/1510; Mailstop UP1110
1250 S. Collegeville Rd.
Collegeville, PA 19426
(610) 917-4459
lori.k.gavrin@gsk.com



Amanda Bryant-Friedrich (2015-2017)

The University of Toledo
Dept of Medicinal and Biological Chemistry
2801 W. Bancroft St.
Toledo, OH 43606
(419) 530-1940
amanda.bryant-friedrich@utoledo.edu

Jennifer Allen, Ph.D. (2017-2019)

Amgen
One Amgen Center Drive
MS 29-2-C
Thousand Oaks, CA 91320
805-313-5251
jeallen@amgen.com



Robert DeVita, Ph.D. (2015-2017)

Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
New York, NY 10029-6574
212-241-0363
robert.devita@mssm.edu



Julien Papillon, Ph.D. (2017-2019)

Novartis Institutes for BioMedical Research
250 Massachusetts Ave
Cambridge, MA 02139
617-871-7653
julien.papillon@novartis.com



Corey Hopkins, Ph.D. (2017-2019)

College of Pharmacy
Univ of Nebraska Medical Center
Omaha, NE 69198
402-559-9729
corey.hopkins@unmc.edu



Vincent Jo Davisson, Ph.D. (2017-2019)

Purdue University College of Pharmacy
575 Stadium Mall Dr
West Lafayette, IN 47907
765-494-5238
davisson@purdue.edu



Katerina Leftheris, Ph.D. (2015-2017)

Sr. Director, Chemistry
Celgene Corp
10300 Campus Point Drive
Suite 100
San Diego, CA 92121
kleftheris@celgene.com



Paul M. Scola Ph.D. (2017-2019)

Senior Principle Scientist
Bristol Myers Squibb Pharmaceutical Institute
5 Research Parkway
Wallingford, CT 06492
Phone (203) 677-7870
Paul.Scola@bms.com



Kevin S. Currie, Ph.D. (2017-2019)

Gilead Sciences
199 East Blaine Street
Seattle, WA 98102
206-454-7100
kevin.currie@gilead.com



Dan Sutherlin, Ph.D. (2017-2019)

Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
650-438-9615
sutherlin.dan@gene.com

Anna K. Mapp, Ph.D. (2017-2019)

University of Michigan
4215 Life Sciences Institute
210 Washtenaw Ave
Ann Arbor, MI 48109
amapp@umich.edu